A real-world cohort of patients with metastatic pancreatic adenocarcinoma (mPDAC) demonstrated that prophylaxis therapy to alleviate toxic effects was ...

T-DM1 sustained the improvement in invasive disease-free survival over trastuzumab in HER2-positive early breast cancer.

Researchers investigated immune-related adverse effects and characteristics that may predict their incidence in patients receiving ICIs for gastrointestinal cancers.

Adjuvant chest wall irradiation should be omitted in most patients meeting the eligibility criteria for SUPREMO,” said Ian Kunkler, MB BChir.